Eli Lilly and Company (NYSE:LLY) Stock Position Boosted by Fisher Asset Management LLC

Fisher Asset Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 3.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,058,101 shares of the company’s stock after purchasing an additional 169,391 shares during the quarter. Eli Lilly and Company comprises 1.8% of Fisher Asset Management LLC’s investment portfolio, making the stock its 8th largest holding. Fisher Asset Management LLC owned 0.53% of Eli Lilly and Company worth $4,481,175,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Daiwa Securities Group Inc. raised its stake in shares of Eli Lilly and Company by 19.4% during the third quarter. Daiwa Securities Group Inc. now owns 135,365 shares of the company’s stock worth $119,925,000 after purchasing an additional 21,975 shares during the last quarter. Hartford Funds Management Co LLC increased its holdings in Eli Lilly and Company by 4.0% in the third quarter. Hartford Funds Management Co LLC now owns 1,418 shares of the company’s stock valued at $1,256,000 after buying an additional 55 shares in the last quarter. Pekin Hardy Strauss Inc. raised its holdings in Eli Lilly and Company by 13.3% during the third quarter. Pekin Hardy Strauss Inc. now owns 1,536 shares of the company’s stock worth $1,361,000 after purchasing an additional 180 shares during the last quarter. Summit Trail Advisors LLC increased its position in shares of Eli Lilly and Company by 10.5% in the third quarter. Summit Trail Advisors LLC now owns 7,549 shares of the company’s stock valued at $6,688,000 after buying an additional 718 shares in the last quarter. Finally, Cahill Financial Advisors Inc. raised its position in Eli Lilly and Company by 11.8% during the third quarter. Cahill Financial Advisors Inc. now owns 247 shares of the company’s stock worth $219,000 after acquiring an additional 26 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 0.3 %

NYSE LLY opened at $748.01 on Monday. The firm has a market capitalization of $710.10 billion, a PE ratio of 80.87, a price-to-earnings-growth ratio of 2.83 and a beta of 0.43. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53. The company has a 50-day simple moving average of $865.01 and a 200-day simple moving average of $870.32. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. On average, equities analysts forecast that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Citigroup upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Finally, Barclays lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,007.94.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.